Vaishali Pharma Limited (VAISHALI) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Vaishali Pharma Limited ₹2.79, price ₹8.38, upside -66.7%, quality 27 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Vaishali Pharma Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range ₹4.88 – ₹42.57 · fair‑value band ₹1.85 – ₹4.09 · the ₹8.38 price screens above the ₹2.79 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Vaishali Pharma in your weekly email
Every Wednesday you see whether Vaishali Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally.
Show more
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, anti"malarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-viral, anti-epileptic, anti-asthmatic, enzymes, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helminitic. The company also provides formulations, including antibiotics, antibacterial, anti-platelet, laxative, anti-ulcer, enzymes, anti-asthmatic, anti-malarial, anti-cold, anti-allergic, anti-viral, anti-psychotic, anti-fungal, vitamins, topical steroids, corticosteroids, anti-inflammatory, analgesic, anti-pyretic, anti-diabetic, cardiac, and other products. In addition, it offers disposable surgical and casting tape products; herbal products; veterinary products; nutraceutical products; and oncology products. The company was formerly known as Vaishali Pharma Private Limited. Vaishali Pharma Limited was founded in 1989 and is based in Mumbai, India.
Stock analysis
Vaishali Pharma Limited (VAISHALI) currently trades at ₹8.38, while our model-based Fair Value estimate is ₹2.79, 66.7% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹6.95 per share, and 0 of the 15 models we run sit above the ₹8.38 price.
Bear case: the Economic Profit group reads lowest at ₹1.53, and 15 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹1.85 (bear) to ₹4.09 (bull), the price of ₹8.38 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Vaishali Pharma Limited reported revenue of ₹1.1B in FY2026 versus ₹758M in FY2022, a compound +9.4%/yr. Reported net income was ₹41.6M in FY2026, compounding +0.9%/yr from FY2022.
Key figures
Market cap ₹1.1B (≈ $11.3M) · P/E ratio 139.7 · P/S ratio 5.35 · EPS (TTM) ₹0.0600 · Net margin 3.8% · Return on equity 6.2% · Return on assets (EBIT) 5.3% · Operating margin −1.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 27% below its 52-week high and 72% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −67%, VAISHALI screens richer than that median.
Fair Value models
Bear ₹1.85Fair Value ₹2.79Bull ₹4.09
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹0.0304 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+9.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.1%
Start year 2021 (pandemic). Over 10 years: +5.0% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.7%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−20.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−20.3%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−20.3% vs −2.0%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 3%
Start year 2021 (pandemic)
⚠ Revenue per share shrinking 2.8%/yr over ~10Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Compare Vaishali Pharma Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 581 stocks
Beats the industry median on 3/12 measures
Overall it trails its industry peers.
Valuation
Quality Score27 · Bottom 25%
Fair Value upside−66.7% · Bottom 25%
Profitability
Return on equity (TTM)6.2% · Below median
Return on assets1.9% · Below median
Net margin (TTM)3.8% · Below median
Operating margin (TTM)−1.3% · Bottom 25%
Growth and dividend
Revenue growth−16.5% · Bottom 25%
Balance sheet
Debt / equity0.06× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)139.7× · Priciest 25%
P/B1.58× · Cheaper than median
P/S (TTM)1.00× · Cheaper than median
EV/EBITDA29.8× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)0· sector 26
PAST (return on equity)25· sector 27
HEALTH (low debt)97· sector 96
DIVIDEND (yield)0· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Vaishali Pharma Limited (VAISHALI) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of ₹2.79 versus a price of ₹8.38, about −67% upside (overvalued).
What is the fair value of VAISHALI?
Our model-based fair value for Vaishali Pharma Limited is ₹2.79 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹8.38.
What is the quality score of VAISHALI?
Vaishali Pharma Limited has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vaishali Pharma Limited (VAISHALI)?
Our model-based price target is the fair value of ₹2.79 (as of Sep 27, 2026) from 15 valuation models. Cautious scenario ₹1.85, optimistic scenario ₹4.09. It is a calculation from audited fundamentals, not an analyst target.
What is the Vaishali Pharma Limited stock forecast for 2026?
Our models put fair value at ₹2.79, about −67% upside versus a price of ₹8.38 (overvalued). Cautious scenario ₹1.85, optimistic scenario ₹4.09. The calculation is refreshed regularly with new filings.
What is the revenue of Vaishali Pharma Limited (VAISHALI)?
Vaishali Pharma Limited reported trailing-twelve-month revenue of about ₹1.1B (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Vaishali Pharma Limited (VAISHALI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vaishali Pharma Limited it is ₹2.79 per share (as of Sep 27, 2026), against a price of ₹8.38. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Vaishali Pharma Limited stock overvalued or undervalued in 2026?
As of Sep 27, 2026, VAISHALI trades above its calculated fair value: price ₹8.38, fair value ₹2.79, a gap of about −67% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VAISHALI?
No. The price is what the market pays today (₹8.38); the fair value is what the company's own numbers justify (₹2.79). For Vaishali Pharma Limited the two are ₹5.59 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vaishali Pharma Limited worth?
The market values Vaishali Pharma Limited at about ₹1.1B (market capitalisation, as of Sep 27, 2026). Per share that is ₹8.38; our models calculate a fair value of ₹2.79 per share.
What do the bullish and bearish scenarios say about VAISHALI?
Our models span a range for Vaishali Pharma Limited: cautious scenario ₹1.85, base ₹2.79, optimistic ₹4.09 per share (as of Sep 27, 2026, price ₹8.38). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of VAISHALI?
Vaishali Pharma Limited trades at a price-to-earnings ratio of 139.7 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹2.79 is built from several models across several years. Other multiples: P/B 1.6, P/S 1.0, EV/EBITDA 29.8.
How solid is the balance sheet of Vaishali Pharma Limited (VAISHALI)?
Balance-sheet figures for Vaishali Pharma Limited (as of Sep 27, 2026): return on equity 6.2%, debt of 0.06 per unit of equity. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is VAISHALI from its 52-week high?
Vaishali Pharma Limited trades at ₹8.38, about 27% below its 52-week high of ₹11.44 and 72% above the low of ₹4.88 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹2.79 is for.
Which stocks are comparable to Vaishali Pharma Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vaishali Pharma Limited stock attractive at the current price?
The data as of Sep 27, 2026: price ₹8.38, calculated fair value ₹2.79 (−67%), Quality Score 27/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VAISHALI calculated?
We run Vaishali Pharma Limited through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹2.79, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Vaishali Pharma Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vaishali Pharma Limited (VAISHALI)?
The closing price on Oct 1, 2026 was ₹8.38. Our model-based fair value is ₹2.79, about −67% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vaishali Pharma Limited right now?
The price sits above even our optimistic bull case (₹4.09). The favourable scenario is already priced in. Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (₹1.85 to ₹4.09) leaves room in how you read the outcome.
Key figures of Vaishali Pharma Limited
How large is the market capitalisation of Vaishali Pharma Limited (VAISHALI)?
The market capitalisation of Vaishali Pharma Limited is ₹1.1B (≈ $11.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vaishali Pharma Limited (VAISHALI)?
The price-to-sales ratio of Vaishali Pharma Limited is 5.35 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Vaishali Pharma Limited (VAISHALI)?
Earnings per share at Vaishali Pharma Limited are ₹0.0600 (price ÷ EPS = P/E 139.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Vaishali Pharma Limited (VAISHALI)?
The net margin of Vaishali Pharma Limited is 3.8% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vaishali Pharma Limited (VAISHALI)?
The return on equity (ROE) of Vaishali Pharma Limited is 6.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vaishali Pharma Limited (VAISHALI)?
On an EBIT basis the return on assets of Vaishali Pharma Limited is 5.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vaishali Pharma Limited (VAISHALI)?
The operating margin of Vaishali Pharma Limited is −1.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vaishali Pharma Limited (VAISHALI)?
Revenue at Vaishali Pharma Limited is growing −16.5% versus a year earlier (3y avg +16.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Vaishali Pharma Limited (VAISHALI)?
Earnings per share at Vaishali Pharma Limited are growing +2.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Vaishali Pharma Limited (VAISHALI) generate?
The free cash flow of Vaishali Pharma Limited is −₹197M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Vaishali Pharma Limited (VAISHALI) carry?
The net debt of Vaishali Pharma Limited is ₹175M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Vaishali Pharma Limited in the live analysis
One click puts Vaishali Pharma Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
